| abstract |
A compound represented by the formula (1) or a pharmaceutically acceptable salt thereof, which has an inhibitory action in the fractalkine-CX3CR1 pathway: wherein R represents unsubstituted or has 1 to 3 substituents selected from the substituent group A a C1-6 alkyl group which is unsubstituted or has 1 to 3 substituents selected from the substituent group A or which is unsubstituted or has 1 to 3 substituents selected from the group of substituents. a C3-8 cycloalkenyl group of the substituent of A, X represents a C1-6 alkyl group, Y and Z are the same or different from each other and each represents a halogen atom or is unsubstituted or has 1 to 3 selected from the group of substituents A C1-6 alkyl group of the substituent of B, n represents 0 or 1, the substituent group A is composed of a halogen atom, and the substituent group B is composed of a halogen atom. |